Archive
Continued mass vaccination will only push the evolutionary capacity of SARS-CoV-2 Spike protein beyond the Omicron version.
By Geert Vanden Bossche 30th November 2021. Find Article Here:-
‘Omicron is more infectious!’ ‘Omicron causes a milder course of disease!’ ‘Omicron escapes vaccine- mediated immunity!’ ‘Omicron has an astonishing number of mutations within the spike (S) protein!’ ‘Omicron will kill itself since it has too many mutations; these will end up incapacitating viral replication!’ ‘Omicron is ominous.’ ‘Omicron is harmless.’ ‘Omicron was bred by an HIV patient.’ ‘South-Africa is to be blamed for spreading Omicron!’ ‘Regardless of all the above, we need new vaccines: anti-Omicron vaccines! Such vaccines will tame Omicron, put a halt to the pandemic and force Omicron into endemicity!’
Neither Key Opinion Leaders (KOLs) nor public health (PH) understand anything related to the evolutionary kinetics of this pandemic; this hasn’t changed at all with the appearance of Omicron. Hard- core scientists spend much time on the molecular stamp collection of a plethora of steadily arising SARS- CoV-2 variants but can’t see the forest for the trees. Clinicians are puzzled by the different manifestations of the disease. The vaccine industry doesn’t care about any of the above as long as they can sell a product carrying a name (‘vaccine’) that will soon be banned from the medical vade mecum.
Scientific naivete combined with arrogant megalomania has led the mighty alliance of PH-KOL and Industry to dramatically underestimate the evolutionary capacity of SARS-CoV-2 when it is put under widespread immune pressure. There can be no doubt that Omicron is only one such example of this and that other variants harboring a similar panoply of S-directed mutations will soon emerge in other countries. There is, indeed, no reason to believe that identical conditions of suboptimal population-level immune pressure on SARS-CoV-2 infectiousness combined with widespread infectious pressure would lead to different results. Alternatively, countries which – thanks to mass vaccination – have prepared their populations to serve as an excellent breeding ground for more infectious variants will exhibit a high level of hospitality to Omicron and its peers.
As the scientifically perverse narrative continues to add fuel to the fire, it is difficult to believe that Omicron will be the end station of the pandemic train that’s out of control. Omicron is likely to start out as a mild disease because short-lived, poorly functional anti-S antibodies (Abs) that resulted from previous asymptomatic infection (e.g., with another previously dominant variant) will no longer recognize Omicron. It is, indeed, highly likely that resistance of Omicron will not be limited to vaccinal Abs but also to naturally induced low affinity Abs that result from asymptomatic/ mild infection. Consequently, Abs from such previous infection would no longer compete with relevant innate Abs for binding to the virus. Individuals who previously contracted asymptomatic/ mild infection will, therefore, be able to fully rely on their first line of immune defense to deal with Omicron. This will leave our ‘experts’ with the impression that the virus (in fact Omicron) is becoming less virulent (than Delta) and is on its way to transit into endemicity. However, the overall pattern of ‘mild’ disease would only prevail until Omicron becomes dominant and causes high infection rates. When this happens, short-lived, low affinity anti-S Abs will start to compete with innate Abs in an increasing part of the population as a direct result of the enhanced likelihood of re- exposure shortly after previous infection. High Omicron infection rates will prevent short-lived, poorly functional anti-S Abs from declining in large parts of the population. This, combined with continued mass vaccination with (inevitable?) anti-Omicron vaccines, will enable large populations to exert immune pressure on Omicron’s infectiousness. None of these immune responses is, however, capable of curtailingviral transmission (it’s now widely acknowledged that the type of C-19 vaccines used by the industry is not capable of blocking transmission).
Mass vaccination promotes viral resistance to C-19 vaccines. Viral resistance drives enhanced infectiousness of SARS-CoV-2 (e.g., Omicron) and may ultimately enable SARS-CoV-2 to utilize alternative cell surface determinants to enter permissive cells.
I am convinced that sustained suboptimal immune pressure will ultimately lead to allosteric mutations (1) of S protein. Such mutation(s) would not prevent neutralizing Abs from binding to S protein but alter the receptor-binding domain (RBD) in ways that enable domains not recognized by these neutralizing Abs to bind to alternative receptor molecules on permissive host cells. Would such allosteric mutation prevent the virus from binding to ACE2? Maybe, or maybe not. It has been well documented that receptor- mediated entry of SARS-CoV-2 is not limited to ACE2 (1). At any rate, this mechanism would no longer allow previously neutralizing Abs acquired upon vaccination or recovery from natural disease to neutralize the virus, but still enable their binding to it. Abs that are still capable of binding to the virus without neutralizing it are at risk of causing Ab-dependent enhancement of disease (ADE). Even though the intrinsic virulence of the virus is unlikely to change (as there is no evidence of immune pressure being placed on virulence genes), the occurrence of ADE would have the same effect because it enhances and accelerates viral pathogenicity. When this happens, we’re likely to generate a situation that resembles the one described for Marek’s disease, although using a different pathway to cause devastating disease (2). Whereas Marek’s virus is so virulent that it breaks through the innate immune defense of the host (poultry) and stays ahead of protective adaptive immunity in unvaccinated chicken, an allosteric SARS- CoV-2 variant would not only break through the innate immune response of vaccinees (due to vaccine- mediated suppression of relevant innate Abs) and resist vaccinal Abs (by bypassing traditional receptor domains within ACE2), but also become more pathogenic due to ADE.
It is undeniable that mass vaccination will only drive the virus to fully exploit its evolutionary capacity, including – if needed – its ability to use alternate receptor domains on permissive cells. The fitness cost that may come with such a dramatic mutation is likely to be rewarded with enhanced pathogenicity. I am truly afraid that these dynamics will eventually allow for the natural selection of individuals with uncompromised innate immunity while eliminating those without it. While such natural selection would lead to an eradication of SARS-CoV-2 as innate immunity sterilizes the virus and blocks transmission, the consequences would be unimaginable – the price paid for ending the pandemic by virus eradication is not comparable to the one paid for by generating herd immunity and allowing the virus to enter an endemic state. Those who are enforcing mass vaccination are opting for the former instead of the latter, an act that will be remembered as the deadliest sin ever.
References:
- https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7883063/
- https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1002198&type=printable
(1) For the purpose of this article, allosteric mutation is defined as a change in an immunogenic, S-associated domain that is situated outside of the RBD and the recognition of which by antiviral Abs leads to a conformational change in the RBD, thereby preventing binding of neutralizing Abs and enabling binding of the RBD to cell surface- expressed determinants that are different from those mediating ACE-2-mediated cell entry of the original Wuhan strain and classical variants (e.g., α, β, γ, δ)
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
Anna De Buisseret, Senior UK Lawyer, ex Military, talks on legality of vaccination mandates, Covid as a Bioweapon and corruption of the Judiciary and the Police.
Posted 9th November 2021. (But actually from July 2021). Find 30min Video/Audio Here:-
The Global Public Private Partnership.
Find larger, magnifiable version on the web Here:-
Unvaccinated workers to be sacked under mining giant, Anglo American plans.
BySam Hall 1st December 2021. Find Article Here:-
Its main shareholder is Black Rock. Have a look at this from The WEF website….and join the dots…
https://www.weforum.org/organizations/anglo-american-plc
FTSE 100 mining giant’s vaccine demands will apply to all of its 95,000 employees worldwide and take effect early next year.
The mining giant Anglo American is planning to dismiss staff who refuse to be vaccinated against Covid, including those in the UK, The Telegraph can reveal.
As the omicron variant spreads, the FTSE 100 owner of De Beers diamonds is consulting its employees about the new rules, which it intends to introduce in the first few months of next year.
Anglo has more than 95,000 employees and contractors worldwide, including 1,300 workers at the new Woodsmith Mine in North Yorkshire and hundreds more at its London headquarters.
Documents seen by The Telegraph indicate that when introduced, the vaccine requirement will apply to all employees, contractors and any visitors to Anglo sites. It will also apply to all new joiners.
The timing and implementation of the policy will vary around the world depending on differing national legislation. Exemptions to the policy will only be considered on medical grounds.
The company is believed to have already rolled out a vaccine mandate at some of its sites in Canada.
Anglo employees will be told that if they refuse to disclose their vaccination status to the company, this lack of proof will mean they will be considered as unvaccinated.
An internal update about the proposals states that employees will need to be vaccinated “to be able to perform their role” and those who refuse may be let go “as a last resort”.
It adds that if a vaccine mandate is introduced, employees would be “given a reasonable amount of time to get vaccinated prior to any consequences being imposed.”
The report also states that any such requirement “would only apply where there is good availability and access to vaccines”. The company operates mines across several countries in southern Africa with low vaccine uptakes, including 26 mines in South Africa as well as sites in Botswana, Namibia and Zimbabwe.
Anglo is thought to be considering introducing a mandate now because of the improved availability of vaccines around the world. In its report, the company also references certain governments mandating vaccines for access to public services as a justification for the measure.
The company said that mine workers can be at risk of covid due to the “inherent nature of some mining activities” and that this also applies to office-based employees who “typically work in confined settings and interact in communal spaces”.
In 2020 Anglo had a revenue of over £30bn. As well as dominating diamond supplies, one of its subsidiaries is the world’s largest producer of platinum.
Dr Elton Dorkin, head of health at the company, said: “Throughout the last 18 months, we have had strict health and testing measures in place across all our operations and offices, and have been strongly encouraging our employees to be vaccinated.
“This has included setting up our own vaccination facilities, where permitted, to make it as easy as possible for our employees in South Africa, given the breadth of our own health infrastructure there. Requiring vaccination for access is the next step, given that vaccination is the best defence available.”
Last week, Dominic Raab, the deputy prime minister, appeared to rule out mandatory vaccinations in the UK outside of health and social care settings.
He said: “Of course we have looked at the specific considerations that need to apply in the NHS and to protect residents of care homes, but it has never even been in our Plan B to have mandatory vaccines and it still isn’t.”
However, thousands of City workers have been told they must wear masks in the office as fears over the new covid strain mount.
HSBC, EY and Aviva are among those to have reinstated mask mandates, with Aviva the latest to make daily lateral flow tests compulsory for anyone entering its buildings.
Some have also been warned about attending large gatherings over Christmas, after a number of major City events were cancelled this week.
The European Commission president, Ursula von der Leyen, said on Wednesday that broader vaccine mandates may also need to be considered within the European Union.
‘Amazing science’: researchers find xenobots can give rise to offspring.
By Nicola Davis 29th November 2021. Find Article Here:-
Xenobots are synthetic lifeforms made by cells from frog embryos and assembling them into clusters.
Xenobots. The parent organism in red next to an offspring cell coloured green. Photograph: Wyss Institute.
Some species do it in pairs, some without knowing the other parties involved, and some even do it on their own: when it comes to replication, nature is nothing if not versatile.
Now researchers say they have found that clusters of frog cells can undergo a form of replication never before seen in plants or animals. The spherical clumps, known as xenobots, can give rise to “offspring” by sweeping up loose cells and swashing them into yet more clusters.
“These things move around in the dish and make copies of themselves,” said Prof Josh Bongard, of the University of Vermont, a co-author of the research.
Xenobots were first announced last year, and are what are known as “living robots”– synthetic lifeforms made by taking a few thousand cells from frog embryos and assembling them into clusters about 1mm in size.
Xenobots have no digestive system or neurons, and naturally fall apart after about two weeks. Bongard said the xenobots in the current study could propel themselves around using hair-like projections called cilia.
“They definitely do not grow into frogs, they actually keep the form that we impose on them. And they look and act in ways very different from normal frog,” he said.
One of those ways is the production of offspring. Anything that makes a copy of itself can be said to replicate, Bongard noted. But plants and animals have previously been found to do this by reproduction – mechanisms that range from the asexual process of budding to giving birth.
Writing in the Proceedings of the National Academy of Sciences, Bongard and colleagues report that xenobots take a very different approach called kinematic self-replication – a process previously seen for molecules but not organisms.
“Kinematic self-replication in molecules was definitely important at the start of life on Earth. But we don’t know whether this form of replication, which we now see in groups of cells, played a role in the life’s origins,” Bongard said.
The team made their discovery by watching the actions of xenobots in petri dishes containing room-temperature pondwater and loose cells from frog embryos.
“[The xenobots] move around in the dish in this corkscrew pattern and they crash into other loose cells, and sort of just smush and push them [into piles],” Bongardsaid.
The team found that as the cells are sticky, they can – if a pile is large enough – form a new, moving cluster over five days: a child xenobot.
But there is a hitch. “It turns out that these xenobots will replicate once, one generation, they will make children. But the children are too small and weak to make grandchildren,” said Bongard.
Using artificial intelligence, the researchers found that if the xenobots were formed into certain shapes, such as that of the video game character Pac-Man, replication continued for further generations.
Bongard said the hope was that self-replicating machines could eventually be developed to do useful work, with the team’s computer simulations suggesting the xenobots could fix electrical circuits.
“These are very small, biodegradable and biocompatible machines, and they’re perfectly happy in freshwater,” he said, adding that near-term applications could include collecting microplastics from waterways.
In the long-term, biobots made from our own cells could even be used in the body to remove the need for surgery, said Bongard.
Prof Mark Miodownik, the director of the Institute of Making at University College London, welcomed the research, saying it was “amazing science and another step closer to animate materials”.
The Truth is Where? 
